Search Results - "Whiteside, Garth"

Dynamic changes in the microRNA expression profile reveal multiple regulatory mechanisms in the spinal nerve ligation model of neuropathic pain by von Schack, David, Agostino, Michael J, Murray, B Stuart, Li, Yizheng, Reddy, Padmalatha S, Chen, Jin, Choe, Sung E, Strassle, Brian W, Li, Christine, Bates, Brian, Zhang, Lynn, Hu, Huijuan, Kotnis, Smita, Bingham, Brendan, Liu, Wei, Whiteside, Garth T, Samad, Tarek A, Kennedy, Jeffrey D, Ajit, Seena K

“…Neuropathic pain resulting from nerve lesions or dysfunction represents one of the most challenging neurological diseases to treat. A better understanding of…”
Get full text

An industry perspective on the role and utility of animal models of pain in drug discovery by Whiteside, Garth T., Pomonis, James D., Kennedy, Jeffrey D.

“…•Evidence that new pain drug discovery failures are due to insufficient efficacy is poorly documented.•Discovery of new drugs requires data from many assays in…”
Get full text

Loss of Retrograde Endocannabinoid Signaling and Reduced Adult Neurogenesis in Diacylglycerol Lipase Knock-out Mice by Gao, Ying, Vasilyev, Dmitry V, Goncalves, Maria Beatriz, Howell, Fiona V, Hobbs, Carl, Reisenberg, Melina, Shen, Ru, Zhang, Mei-Yi, Strassle, Brian W, Lu, Peimin, Mark, Lilly, Piesla, Michael J, Deng, Kangwen, Kouranova, Evguenia V, Ring, Robert H, Whiteside, Garth T, Bates, Brian, Walsh, Frank S, Williams, Gareth, Pangalos, Menelas N, Samad, Tarek A, Doherty, Patrick

“…Endocannabinoids (eCBs) function as retrograde signaling molecules at synapses throughout the brain, regulate axonal growth and guidance during development,…”
Get full text

A randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile by Arendt-Nielsen, Lars, Harris, Steve, Whiteside, Garth T., Hummel, Michele, Knappenberger, Terri, O'Keefe, Sarah, Kapil, Ram, Kyle, Don

“…This experimental, translational, experimental pain, single-center, randomized, double-blind, single-dose, 3-treatment, 3-period cross-over proof-of-concept…”
Get full text

The nociceptin/orphanin FQ receptor partial agonist sunobinop promotes non-REM sleep in rodents and patients with insomnia by Whiteside, Garth T, Kyle, Donald J, Kapil, Ram R, Cipriano, Alessandra, He, Ellie, Zhou, Mingyan, Shet, Manjunath S, Hummel, Michele, Knappenberger, Terri, Fukumura, Kazuya, Matsuo, Yoshiyuki, Uehira, Masahiro, Hiroyama, Shuichi, Takai, Nozomi, Willsie, Sandra K, Harris, Stephen C

“…Insomnia is a common disorder that poses a significant public health burden. Current treatments for insomnia primarily target aminobutyric acid or orexin…”
Get full text

The nociceptin/orphanin FQ receptor partial agonist sunobinop promotes non-REM sleep in rodents and patients with insomnia by Whiteside, Garth T, Kyle, Donald J, Kapil, Ram P, Cipriano, Alessandra, He, Ellie, Zhou, Mingyan, Shet, Manjunath S, Hummel, Michele, Knappenberger, Terri, Fukumura, Kazuya, Matsuo, Yoshiyuki, Uehira, Masahiro, Hiroyama, Shuichi, Takai, Nozomi, Willsie, Sandra K, Harris, Stephen C

“…The potent and partial agonist sunobinop activates the nociceptin/orphanin-FQ peptide receptor and promotes non-REM sleep in rodents and patients with insomnia…”
Get full text

Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system by Chanda, Pranab K, Gao, Ying, Mark, Lilly, Btesh, Joan, Strassle, Brian W, Lu, Peimin, Piesla, Michael J, Zhang, Mei-Yi, Bingham, Brendan, Uveges, Albert, Kowal, Dianne, Garbe, David, Kouranova, Evguenia V, Ring, Robert H, Bates, Brian, Pangalos, Menelas N, Kennedy, Jeffrey D, Whiteside, Garth T, Samad, Tarek A

“…Endocannabinoids are lipid molecules that serve as natural ligands for the cannabinoid receptors CB1 and CB2. They modulate a diverse set of physiological…”
Get more information

Evaluation of sunobinop for next-day residual effects in healthy participants by Cipriano, Alessandra, Kapil, Ram P, Zhou, Mingyan, Shet, Manjunath S, Harris, Stephen C, Apseloff, Glen, Whiteside, Garth T

“…Sunobinop is a novel, potent, selective partial agonist at nociceptin/orphanin FQ peptide (NOP) receptors. The primary objective of this randomized,…”
Get full text

Particulate levodopa nose-to-brain delivery targets dopamine to the brain with no plasma exposure by Dimiou, Savvas, Lopes, Rui M., Kubajewska, Ilona, Mellor, Ryan D., Schlosser, Corinna S., Shet, Manjunath S., Huang, Hugh, Akcan, Ozgur, Whiteside, Garth T., Schätzlein, Andreas G., Uchegbu, Ijeoma F.

“…[Display omitted] Levodopa (L-DOPA) is an oral Parkinson’s Disease drug that generates the active metabolite - dopamine (DA) in vivo. However, oral L-DOPA…”
Get full text

Pharmacological evaluation of NSAID-induced gastropathy as a “Translatable” model of referred visceral sensitivity by Hummel, Michele, Knappenberger, Terri, Reilly, Meghan, Whiteside, Garth T

“…AIM To evaluate whether non-steroidal anti-inflammatory drugs(NSAIDs)-induced gastropathy is a clinically predictive model of referred visceral…”
Get full text

Depression-like phenotype following chronic CB1 receptor antagonism by Beyer, Chad E, Dwyer, Jason M, Piesla, Michael J, Platt, Brian J, Shen, Ru, Rahman, Zia, Chan, Karen, Manners, Melissa T, Samad, Tarek A, Kennedy, Jeffrey D, Bingham, Brendan, Whiteside, Garth T

“…Abstract Rimonabant was the first clinically marketed cannabinoid (CB)1 receptor antagonist developed to treat obesity. Unfortunately, CB1 receptor antagonism…”
Get full text

The persistence of a long-term negative affective state following the induction of either acute or chronic pain by Hummel, Michele, Lu, Peimin, Cummons, Terri A., Whiteside, Garth T.

“…Clinically, pain is a complex phenomenon consisting of both sensory and affective aberrations that can persist indefinitely. Pre-clinically, several animal…”
Get full text

Safety, Tolerability, and Pharmacokinetics of Single‐ and Multiple‐Ascending Doses of Sunobinop in Healthy Participants by Cipriano, Alessandra, Kapil, Ram P., Zhou, Mingyan, Shet, Manjunath S., Whiteside, Garth T., Willsie, Sandra K., Harris, Stephen C.

“…Sunobinop is an investigational, potent, selective partial agonist at the nociceptin/orphanin FQ peptide receptor in vitro. Three phase 1 studies were…”
Get full text

Current and potential pharmacological treatment options for insomnia in patients with alcohol use disorder in recovery by Roehrs, Timothy A., Auciello, Jessica, Tseng, Jack, Whiteside, Garth

“…Alcohol use disorder (AUD) is characterized by dysfunction in motivational, mood‐stress regulation, and sleep systems that interact in complex ways to heighten…”
Get full text

Targeting CB2 receptors and the endocannabinoid system for the treatment of pain by Anand, Praveen, Whiteside, Garth, Fowler, Christopher J, Hohmann, Andrea G

“…Abstract The endocannabinoid system consists of the cannabinoid (CB) receptors, CB1 and CB2 , the endogenous ligands anandamide (AEA, arachidonoylethanolamide)…”
Get full text

Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy by Valenzano, Kenneth J., Tafesse, Laykea, Lee, Gary, Harrison, James E., Boulet, Jamie M., Gottshall, Susan L., Mark, Lilly, Pearson, Michelle S., Miller, Wendy, Shan, Shen, Rabadi, Leyana, Rotshteyn, Yakov, Chaffer, Suzanne M., Turchin, Paul I., Elsemore, David A., Toth, Mathew, Koetzner, Lee, Whiteside, Garth T.

“…To date, two cannabinoid receptors have been identified, CB1 and CB2. Activation of these receptors with non-selective cannabinoid receptor agonists reduces…”
Get full text

Pain is a salient “stressor” that is mediated by corticotropin-releasing factor-1 receptors by Hummel, Michele, Cummons, Terri, Lu, Peimin, Mark, Lilly, Harrison, James E., Kennedy, Jeffrey D., Whiteside, Garth T.

“…Corticotropin-releasing factor (CRF) plays a major role in controlling the body’s response to stress. Because painful conditions are inherently stressful, we…”
Get full text

Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models by Piesla, Michael J, Leventhal, Liza, Strassle, Brian W, Harrison, James E, Cummons, Terri A, Lu, Peimin, Whiteside, Garth T

“…Abstract Validation of gait analysis has the potential to bridge the gap between data from animal pain models and clinical observations. The goal of these…”
Get full text

CNS penetration of small molecules following local inflammation, widespread systemic inflammation or direct injury to the nervous system by Lu, Peimin, Gonzales, Cathy, Chen, Yi, Adedoyin, Adedayo, Hummel, Michele, Kennedy, Jeffrey D., Whiteside, Garth T.

“…We sought to investigate effects of local and systemic inflammation on CNS permeability of small molecules and compare these to effects of direct injury to the…”
Get full text

Pharmacological characterisation of a rat model of incisional pain by Whiteside, Garth T, Harrison, James, Boulet, Jamie, Mark, Lilly, Pearson, Michelle, Gottshall, Susan, Walker, Katharine

“…Both clinical and preclinical models of postsurgical pain are being used more frequently in the early evaluation of new chemical entities. In order to assess…”
Get full text